MetaCap

AC Immune SA (ACIU) vs Faeth Therapeutics (FTH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Faeth Therapeutics (FTH) has outperformed AC Immune SA (ACIU) over the past year, losing 9.6% versus a loss of 35.0%. Over five years, ACIU leads with a -62.3% price change compared with -95.0% for FTH. Faeth Therapeutics is the larger company by market cap ($203.7 million vs $193.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACIU-35.00%FTH-9.64%
+379%+162%-55%
Nov 21, 20251 yearNov 20, 2026
ACIU-64.35%FTH-95.34%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACIU versus FTH key metrics
MetricACIUFTH
Share price$1.95$7.88
Market cap$193.88M$203.65M
1-day change-8.45%-9.32%
YTD return-37.90%-26.15%
1-year return-35.00%-9.64%
5-year return-62.28%-94.96%
Forward P/E2.84—
EPS (TTM)$-0.44$-22.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-21.09M
52-week high$3.90$42.14
52-week low$1.93$7.45
Distance from 52-week high-50.00%-81.30%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+331.28%+612.56%
Average volume198.81K500.25K
Shares outstanding99.43M25.84M
Employees9029
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FTH has outperformed ACIU by 25.4 percentage points over the past year.

About AC Immune SA

ACIU stock →

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees

About Faeth Therapeutics

FTH stock →

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

ACIU vs FTH FAQ

Which is bigger, AC Immune SA or Faeth Therapeutics?

Faeth Therapeutics (FTH) is larger, with a market capitalization of $203.65M compared with $193.88M for AC Immune SA (ACIU).

Which stock has performed better over the past year, ACIU or FTH?

FTH returned -9.64% over the past 12 months, compared with -35.00% for ACIU (price return, excluding dividends). Past performance does not predict future results.

Are AC Immune SA and Faeth Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons